In addition, the dynamic changes of HER2 expression in HER2-low tumors between primary and metastatic/recurrent/NAC BCs further support the roles of endocrine therapy, chemotherapy and radiation therapy in shaping the HER2-low expression in BC [22,45,46]. Here, ERBB2 is linked to breast cancer.